Finally, a hazard ratio analysis of patients with ER+ BC found a significantly increased risk for lower survival with increased tumor expression of IFI27, IFI44, IFI44L, IFI6, IFIT1, IFIT2, IFIT3, ISG15, MX1, OAS1, and OASL (Supplemental Figure 8D). This evidence concerns the gene IFI44 and breast cancer.